The recent announcement by the president regarding the automatic health registration of drugs approved by the FDA and EMA has generated controversy, with experts denouncing that this measure violates Law 419. Lawyer Jaime Olive, president of the National Pharmaceutical Association, expressed his opinion on this in the program "Get Informed About the Truth."
"The president wants to do many things, but we must respect the Constitution and the laws," Olive stated. According to him, this measure contradicts what is established in Law 419, which indicates that all medications entering the country must comply with local health registration requirements through the National Directorate of Pharmacy and Drugs.
Olive highlighted the importance of local regulation to ensure the safety and efficacy of products, avoiding situations where previously approved drugs may turn out to be ineffective or dangerous. The recent decision by the United States to withdraw from the WHO also complicates the situation, as any transaction with the FDA could become void.
The pharmaceutical guild has also questioned the management of public drug purchases, while citizens face shortages in public pharmacies. Olive emphasized the importance of a clear approach to address this issue and the lack of adequate regulation, which has created a crisis of credibility.
From Olive's perspective, the reverse auction, provided for in Law 419, could guarantee lower prices and greater transparency in purchases, but he regretted that authorities are not prioritizing this mechanism. He has requested a formal meeting with the president, the minister of health, and the director of the Social Security Fund to discuss these concerns and propose possible solutions.
